The Investor
11 Nov 2026, 17:42
Lilly Reports Strong One-Year Results for Taltz and Zepbound Combination in Psoriatic Arthritis
Eli Lilly (NYSE: LLY) reported positive 52-week Phase 3b data showing that Taltz and Zepbound used together produced stronger and more durable outcomes than Taltz alone in adults with active psoriatic arthritis and obesity or overweight.
At one year, 43.7% of patients receiving the combination achieved ACR50, indicating at least a 50% improvement in psoriatic arthritis disease activity, compared with 15.7% of patients receiving Taltz alone. Lilly said the difference was already visible by Week 4, before clinically meaningful weight loss had occurred.
The combination also produced substantially stronger weight-loss outcomes. At Week 52, 85.7% of patients receiving Taltz plus Zepbound achieved at least 10% weight reduction, compared with 6.7% on Taltz alone. Meanwhile, 39.2% of combination-treated patients achieved both ACR50 and at least 10% weight loss versus 1.7% with Taltz monotherapy.
Additional measures also favored the combination, including minimal disease activity, physical function, fatigue and inflammatory markers. Lilly reported improvements in metabolic measures including BMI, body weight, systolic blood pressure, glucose, HbA1c, triglycerides and total cholesterol.
Safety findings were generally consistent with the established profiles of both medicines, with most adverse events described as mild to moderate.
The results strengthen Lilly’s broader immunometabolic strategy by suggesting that simultaneously targeting inflammatory disease and obesity may provide greater clinical benefit than treating psoriatic arthritis alone in patients affected by both conditions.
Eli Lilly (NYSE: LLY) reported positive 52-week Phase 3b data showing that Taltz and Zepbound used together produced stronger and more durable outcomes than Taltz alone in adults with active psoriatic arthritis and obesity or overweight.
At one year, 43.7% of patients receiving the combination achieved ACR50, indicating at least a 50% improvement in psoriatic arthritis disease activity, compared with 15.7% of patients receiving Taltz alone. Lilly said the difference was already visible by Week 4, before clinically meaningful weight loss had occurred.
The combination also produced substantially stronger weight-loss outcomes. At Week 52, 85.7% of patients receiving Taltz plus Zepbound achieved at least 10% weight reduction, compared with 6.7% on Taltz alone. Meanwhile, 39.2% of combination-treated patients achieved both ACR50 and at least 10% weight loss versus 1.7% with Taltz monotherapy.
Additional measures also favored the combination, including minimal disease activity, physical function, fatigue and inflammatory markers. Lilly reported improvements in metabolic measures including BMI, body weight, systolic blood pressure, glucose, HbA1c, triglycerides and total cholesterol.
Safety findings were generally consistent with the established profiles of both medicines, with most adverse events described as mild to moderate.
The results strengthen Lilly’s broader immunometabolic strategy by suggesting that simultaneously targeting inflammatory disease and obesity may provide greater clinical benefit than treating psoriatic arthritis alone in patients affected by both conditions.
